Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic LeukemiaWilliam G. Wierda, Anders Österborg, Martin J.S. Dyer et al.|Journal of Clinical Oncology|2010Cited by 587
A Comprehensive Microarray-Based DNA Methylation Study of 367 Hematological NeoplasmsJosé I. Martín‐Subero, Reiner Siebert, Ole Ammerpohl et al.|PLoS ONE|2009Cited by 137
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapyToby A. Eyre, Graham P. Collins, Harriet S. Walter et al.|Haematologica|2018Cited by 137
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C. Thompson, Anthony R. Mato, Rosemary Harrup et al.|Blood Advances|2022Cited by 57
Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphomaAntoine Hollebecque, Monica Mita, Sarit Assouline et al.|Molecular Cancer Therapeutics|2019Cited by 2